BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 23775717)

  • 1. Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms.
    Przychodzen B; Jerez A; Guinta K; Sekeres MA; Padgett R; Maciejewski JP; Makishima H
    Blood; 2013 Aug; 122(6):999-1006. PubMed ID: 23775717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational analysis of splicing machinery genes SF3B1, U2AF1 and SRSF2 in myelodysplasia and other common tumors.
    Je EM; Yoo NJ; Kim YJ; Kim MS; Lee SH
    Int J Cancer; 2013 Jul; 133(1):260-5. PubMed ID: 23280334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. U2AF1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
    Qian J; Yao DM; Lin J; Qian W; Wang CZ; Chai HY; Yang J; Li Y; Deng ZQ; Ma JC; Chen XX
    PLoS One; 2012; 7(9):e45760. PubMed ID: 23029227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alteration of the SETBP1 gene and splicing pathway genes SF3B1, U2AF1, and SRSF2 in childhood acute myeloid leukemia.
    Choi HW; Kim HR; Baek HJ; Kook H; Cho D; Shin JH; Suh SP; Ryang DW; Shin MG
    Ann Lab Med; 2015 Jan; 35(1):118-22. PubMed ID: 25553291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Splicing Factor Mutations in Cancer.
    Bejar R
    Adv Exp Med Biol; 2016; 907():215-28. PubMed ID: 27256388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis.
    Makishima H; Visconte V; Sakaguchi H; Jankowska AM; Abu Kar S; Jerez A; Przychodzen B; Bupathi M; Guinta K; Afable MG; Sekeres MA; Padgett RA; Tiu RV; Maciejewski JP
    Blood; 2012 Apr; 119(14):3203-10. PubMed ID: 22323480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo.
    Shirai CL; Ley JN; White BS; Kim S; Tibbitts J; Shao J; Ndonwi M; Wadugu B; Duncavage EJ; Okeyo-Owuor T; Liu T; Griffith M; McGrath S; Magrini V; Fulton RS; Fronick C; O'Laughlin M; Graubert TA; Walter MJ
    Cancer Cell; 2015 May; 27(5):631-43. PubMed ID: 25965570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes.
    Graubert TA; Shen D; Ding L; Okeyo-Owuor T; Lunn CL; Shao J; Krysiak K; Harris CC; Koboldt DC; Larson DE; McLellan MD; Dooling DJ; Abbott RM; Fulton RS; Schmidt H; Kalicki-Veizer J; O'Laughlin M; Grillot M; Baty J; Heath S; Frater JL; Nasim T; Link DC; Tomasson MH; Westervelt P; DiPersio JF; Mardis ER; Ley TJ; Wilson RK; Walter MJ
    Nat Genet; 2011 Dec; 44(1):53-7. PubMed ID: 22158538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pan-cancer analysis of transcriptome changes associated with somatic mutations in U2AF1 reveals commonly altered splicing events.
    Brooks AN; Choi PS; de Waal L; Sharifnia T; Imielinski M; Saksena G; Pedamallu CS; Sivachenko A; Rosenberg M; Chmielecki J; Lawrence MS; DeLuca DS; Getz G; Meyerson M
    PLoS One; 2014; 9(1):e87361. PubMed ID: 24498085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations.
    Hamilton BK; Visconte V; Jia X; Tabarroki A; Makishima H; Hasrouni E; Abounader D; Kalaycio M; Sekeres MA; Sobecks R; Duong Liu H; Bolwell B; Maciejewski JP; Copelan E; Tiu RV
    Am J Hematol; 2016 Jun; 91(4):406-9. PubMed ID: 26799334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spliceosome mutations in hematopoietic malignancies.
    Hahn CN; Scott HS
    Nat Genet; 2011 Dec; 44(1):9-10. PubMed ID: 22200771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. U2AF1 mutations alter splice site recognition in hematological malignancies.
    Ilagan JO; Ramakrishnan A; Hayes B; Murphy ME; Zebari AS; Bradley P; Bradley RK
    Genome Res; 2015 Jan; 25(1):14-26. PubMed ID: 25267526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome.
    Hong JY; Seo JY; Kim SH; Jung HA; Park S; Kim K; Jung CW; Kim JS; Park JS; Kim HJ; Jang JH
    Anticancer Res; 2015 May; 35(5):3081-9. PubMed ID: 25964599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. U2AF1 mutations alter sequence specificity of pre-mRNA binding and splicing.
    Okeyo-Owuor T; White BS; Chatrikhi R; Mohan DR; Kim S; Griffith M; Ding L; Ketkar-Kulkarni S; Hundal J; Laird KM; Kielkopf CL; Ley TJ; Walter MJ; Graubert TA
    Leukemia; 2015 Apr; 29(4):909-17. PubMed ID: 25311244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts.
    Kang MG; Kim HR; Seo BY; Lee JH; Choi SY; Kim SH; Shin JH; Suh SP; Ahn JS; Shin MG
    BMC Cancer; 2015 Jun; 15():484. PubMed ID: 26115659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired hematopoiesis and leukemia development in mice with a conditional knock-in allele of a mutant splicing factor gene
    Fei DL; Zhen T; Durham B; Ferrarone J; Zhang T; Garrett L; Yoshimi A; Abdel-Wahab O; Bradley RK; Liu P; Varmus H
    Proc Natl Acad Sci U S A; 2018 Oct; 115(44):E10437-E10446. PubMed ID: 30322915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.
    Thol F; Kade S; Schlarmann C; Löffeld P; Morgan M; Krauter J; Wlodarski MW; Kölking B; Wichmann M; Görlich K; Göhring G; Bug G; Ottmann O; Niemeyer CM; Hofmann WK; Schlegelberger B; Ganser A; Heuser M
    Blood; 2012 Apr; 119(15):3578-84. PubMed ID: 22389253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression.
    Wu SJ; Tang JL; Lin CT; Kuo YY; Li LY; Tseng MH; Huang CF; Lai YJ; Lee FY; Liu MC; Liu CW; Hou HA; Chen CY; Chou WC; Yao M; Huang SY; Ko BS; Tsay W; Tien HF
    Am J Hematol; 2013 Nov; 88(11):E277-82. PubMed ID: 23861105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ribosome biogenesis is a downstream effector of the oncogenic U2AF1-S34F mutation.
    Akef A; McGraw K; Cappell SD; Larson DR
    PLoS Biol; 2020 Nov; 18(11):e3000920. PubMed ID: 33137094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Biological and Clinical Consequences of RNA Splicing Factor U2AF1 Mutation in Myeloid Malignancies.
    Zhao Y; Cai W; Hua Y; Yang X; Zhou J
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.